Shares of Novo Nordisk (NVO 4.37%) were moving higher on Wednesday. The company's stock gained 4.9% as of 1:50 p.m. ET, but gained as much as 5.8% earlier in the day. The leg up comes as the S&P 500 (^GSPC 0.26%) gained 0.2%, and the Nasdaq Composite (^IXIC 0.02%) lost 0.1% on the day.
The pharmaceutical giant and maker of Ozempic and Wegovy reported better-than-expected numbers Wednesday morning. The drugmaker delivered 25% year-over-year (YOY) revenue growth, with 2024 sales coming in at $40.5 billion. That exceeded Wall Street's target of $39.5 billion. For Q4, the company reported $11.6 billion in sales -- up 30% YOY -- beating the expected $11.2 billion.
The strong performance was driven by the company's pair of semaglutide drugs, Wegovy and Ozempic. Of the full year's total sales of $40.5 billion, the two were responsible for $24.9 billion. Novo is leading the GLP-1 contest with 52% of the market share, outperforming key rivals like Eli Lilly.
However, as the company struggles to keep up with demand, it is taking on debt to bolster its manufacturing, which could eat into margins.
GLP-1 drugs like Ozempic require injections, severely limiting their adoption. While Novo Nordisk owns the market for now, a pill-based GLP-1 would be a game changer. The company is in a race with Eli Lilly to be first to market in the U.S. Whichever company does so could shift the balance of power significantly.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。